Earnings results for Enlivex Therapeutics (NASDAQ:ENLV)
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.24 and remained the same over the past month at -0.24. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -1 and remained the same over the past month at -1 . none raised and none lowered their forecast.
Enlivex Therapeutics last posted its earnings data on May 18th, 2020. The reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.17. Enlivex Therapeutics has generated ($1.11) earnings per share over the last year. Enlivex Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, July 31st, 2020 based off prior year’s report dates.
Analyst Opinion on Enlivex Therapeutics (NASDAQ:ENLV)
1 Wall Street analysts have issued ratings and price targets for Enlivex Therapeutics in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 285.96%. The high price target for ENLV is $22.00 and the low price target for ENLV is $22.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
Enlivex Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $22.00, Enlivex Therapeutics has a potential upside of 286.0% from its current price of $5.70. Enlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Enlivex Therapeutics (NASDAQ:ENLV)
Enlivex Therapeutics does not currently pay a dividend. Enlivex Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Enlivex Therapeutics (NASDAQ:ENLV)
In the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock. Only 7.15% of the stock of Enlivex Therapeutics is held by institutions.
Earnings and Valuation of Enlivex Therapeutics (NASDAQ:ENLV
Earnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($1.00) to ($1.12) per share. The P/E ratio of Enlivex Therapeutics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Enlivex Therapeutics is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Enlivex Therapeutics has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here